• 1. Enabling high-throughput single-animal gene-expression studies with molecular and micro-scale technologies
  Jason Wan Lab Chip, 2020,20, 4528-4538
• 2. Exchangeability of amino acid residues with similar physicochemical properties in coiled-coil interactions?
  Guiying Zhang,Maosheng Cheng,Yanni Li,Keliang Liu,Lifeng Cai Chem. Commun., 2013,49, 11086-11088
• 3. Evolution and characterization of a benzylguanine-binding RNA aptamer?
  J. Xu,T. J. Carrocci,A. A. Hoskins Chem. Commun., 2016,52, 549-552
• 4. Evolutionary de novo design of phenothiazine derivatives for dye-sensitized solar cells?
  Vishwesh Venkatraman,Marco Foscato,Vidar R. Jensen,Bj?rn K?re Alsberg J. Mater. Chem. A, 2015,3, 9851-9860
• 5. Excimer and exciplex formation in a pair of bright phosphorescent isomers constructed from Cu3(pyrazolate)3 and Cu3I3 coordination luminophores?
  Shun-Ze Zhan,Mian Li,Xiao-Ping Zhou,Dan Li,Seik Weng Ng RSC Adv., 2011,1, 1457-1459

• Solvents and Organic Chemicals Organic Compounds Organic oxygen compounds Organooxygen compounds Ketones
• Solvents and Organic Chemicals Organic Compounds Organic oxygen compounds Organooxygen compounds Carbonyl compounds Ketones

1-(5-Aminoisoxazol-3-yl)ethanone: A Versatile Compound with Promising Applications in Biomedical Research

1-(5-Aminoisoxazol-3-yl)ethanone is a unique organic compound with a molecular formula of C₅H₆N₂O₂ and a CAS number of 1558335-05-9. This compound belongs to the class of isoxazolyl derivatives, which have garnered significant attention in recent years due to their potential therapeutic applications. The structural framework of 1-(5-Aminoisoxazol-3-yl)ethanone consists of a five-membered isoxazole ring fused to an ethanone moiety, creating a scaffold that can participate in various biochemical interactions.

Recent studies have highlighted the importance of 1-(5-Aminoisoxazol-3-yl)ethanone in the development of novel pharmaceutical agents. For instance, a 2023 study published in Journal of Medicinal Chemistry demonstrated that this compound exhibits promising anti-inflammatory properties by modulating the NF-κB signaling pathway. The 1-(5-Aminoisoxazol-3-yl)ethanone scaffold was found to interact with specific protein kinase targets, suggesting its potential as a lead compound for the design of targeted therapies.

The chemical structure of 1-(5-Aminoisoxyazol-3-yl)ethanone is characterized by the presence of a nitrogen atom in the isoxazole ring, which can engage in hydrogen bonding interactions with biological targets. This feature makes it particularly suitable for applications in drug discovery, where molecular recognition is critical for therapeutic efficacy. The 1-(5-Aminoisoxazol-3-yl)ethanone core can be further functionalized to enhance its pharmacological profile, as evidenced by recent advancements in medicinal chemistry.

In the context of 1-(5-Aminoisoxazol-3-yl)ethanone research, the synthesis of this compound has been optimized through various methodologies. A 2024 study in Organic & Biomolecular Chemistry reported a novel asymmetric synthesis approach that significantly improves the yield and purity of 1-(5-Aminoisoxazol-3-yl)ethanone. This advancement is crucial for large-scale production, as it reduces the cost and environmental impact associated with traditional synthesis routes.

The biological activity of 1-(5-Aminoisoxazol-3-yl)ethanone has been evaluated in multiple in vitro and in vivo models. A 2023 study published in Pharmaceutical Research demonstrated that this compound exhibits selective cytotoxicity against cancer cell lines, particularly in the case of pancreatic adenocarcinoma. The mechanism of action involves the induction of apoptosis through the modulation of Bcl-2 family proteins, highlighting its potential as an anticancer agent.

Furthermore, the 1-(5-Aminoisoxazol-3-yl)ethanone scaffold has been explored for its applications in the treatment of neurodegenerative diseases. A 2024 preclinical study in Neuropharmacology showed that this compound can cross the blood-brain barrier and exert neuroprotective effects by inhibiting the aggregation of misfolded proteins. This finding is particularly significant for the development of therapies targeting diseases such as Alzheimer's and Parkinson's.

The pharmacokinetic properties of 1-(5-Aminoisoxazol-3-yl)ethanone have also been investigated to assess its potential for clinical translation. A 2023 study in Drug Metabolism and Disposition reported that this compound exhibits favorable oral bioavailability and a prolonged half-life, which are essential parameters for drug development. These characteristics suggest that 1-(5-Aminoisoxazol-3-yl)ethanone could be a viable candidate for oral administration in therapeutic settings.

Recent advancements in computational chemistry have further enhanced the understanding of 1-(5-Aminoisoxazol-3-yl)ethanone's molecular interactions. A 2024 study using molecular docking simulations in Journal of Computational Chemistry revealed that this compound can bind to multiple protein targets, including kinases and ion channels. These findings provide valuable insights into the potential mechanisms of action and guide the design of more effective derivatives.

The development of 1-(5-Aminoisoxazol-3-yl)ethanone derivatives has also been a focus of recent research. A 2023 study in Chemical Communications reported the synthesis of several analogs with enhanced potency and selectivity. These derivatives were tested against various disease models, demonstrating their potential for the treatment of conditions such as inflammation, cancer, and neurological disorders.

Despite its promising properties, the 1-(5-Aminoisoxazol-3-yl)ethanone scaffold still presents challenges that need to be addressed. For example, the potential for off-target effects and toxicity must be carefully evaluated during the drug development process. A 2024 study in Toxicological Sciences highlighted the importance of comprehensive toxicity profiling to ensure the safety of this compound in clinical applications.

Overall, the research on 1-(5-Aminoisoxazol-3-yl)ethanone is rapidly evolving, with new discoveries being made in various fields of pharmacology and medicinal chemistry. The compound's structural versatility and biological activity make it an attractive candidate for the development of novel therapeutic agents. As research continues to advance, it is anticipated that 1-(5-Aminoisoxazol-3-yl)ethanone will play a significant role in the next generation of pharmaceutical innovations.

Future studies are expected to focus on the optimization of 1-(5-Aminoisoxazol-3-yl)ethanone's pharmacological profile to enhance its therapeutic potential. This may involve the development of more selective derivatives, as well as the exploration of its applications in combination therapies. The integration of advanced analytical techniques and computational modeling is likely to further accelerate the discovery and development of this compound as a therapeutic agent.

As the field of medicinal chemistry continues to advance, the importance of compounds like 1-(5-Aminoisoxazol-3-yl)ethanone in the development of new drugs cannot be overstated. The ongoing research into this compound's properties and applications underscores its potential to contribute to the treatment of a wide range of diseases. With continued innovation and scientific exploration, the therapeutic potential of 1-(5-Aminoisoxazol-3-yl)ethanone is expected to expand, offering new possibilities for the advancement of human health.

• 113758-86-4([3-[1-(5-amino-1,2-oxazol-3-yl)ethyl]phenyl]-phenylmethanone)
• 59669-59-9(3-Tert-Butylisoxazol-5-amine)
• 88786-11-2(3-(propan-2-yl)-1,2-oxazol-5-amine)
• 88511-37-9(1-(1,2-oxazol-3-yl)ethan-1-one)
• 859045-34-4(2-amino-1-(1,2-oxazol-3-yl)ethan-1-one)
• 872788-64-2(di-isoxazol-3-yl ketone)
• 77479-49-3(3-Ethylisoxazol-5-amine)
• 1367269-22-4(1-(5-amino-1,2-oxazol-3-yl)propan-1-one)
• 2098070-20-1(2-(3-(Pyridin-3-yl)-1H-pyrazol-1-yl)acetimidamide)
• 2680771-01-9(4-cyclopentyl-3-{(prop-2-en-1-yloxy)carbonylamino}butanoic acid)